GlassScriptPhysician profile
Ashli Bowling
NPI 1710429113
$2,737.28
in general payments reported to CMS, 2019-2025
17 companies · $873 in 2025
The $873 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.84 · 2023: $723 · 2024: $1,127 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,613 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,612.98 |
| Education | $110.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $760.69 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $564.67 | 2023-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $230.10 | 2023-2025 | |
| Akebia Therapeutics INC | $213.57 | 2023-2024 | Auryxia, Vafseo |
| Astrazeneca Pharmaceuticals LP | $209.47 | 2023-2025 | Farxiga, Brilinta, Lokelma |
| Vifor Pharma, INC. | $147.49 | 2023-2025 | Veltassa, Korsuva |
| Lilly USA, LLC | $137.41 | 2024-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $127.82 | 2024-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $110.46 | 2024-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $81.22 | 2024-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $27.25 | 2024 | Ultomiris |
| Novo Nordisk INC | $25.00 | 2025 | Ozempic |
| Edwards Lifesciences Corporation | $24.53 | 2024 | Sapien 3 Ultra Resilia |
| Pharmacosmos Therapeutics INC. | $24.11 | 2024 | Monoferric |
| Ardelyx, INC. | $20.51 | 2025 | Ibsrela |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.72 | 2024 | Jardiance |
| Ascendis Pharma Endocrinology INC | $16.26 | 2025 | Yorvipath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashli Bowling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.